MX2008013796A - Biomarcadores de infeccion por el virus de hepatitis c. - Google Patents

Biomarcadores de infeccion por el virus de hepatitis c.

Info

Publication number
MX2008013796A
MX2008013796A MX2008013796A MX2008013796A MX2008013796A MX 2008013796 A MX2008013796 A MX 2008013796A MX 2008013796 A MX2008013796 A MX 2008013796A MX 2008013796 A MX2008013796 A MX 2008013796A MX 2008013796 A MX2008013796 A MX 2008013796A
Authority
MX
Mexico
Prior art keywords
activity
gene
protein
subject
hepatitis
Prior art date
Application number
MX2008013796A
Other languages
English (en)
Spanish (es)
Inventor
Ravi K Ramachandran
Matthew W Harding
Paul R Caron
Martyn C Botfield
Brian J Hare
Raj Bandaru
Kevin M Kelliher
Catherine N Cornell
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2008013796A publication Critical patent/MX2008013796A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2008013796A 2006-04-26 2007-04-25 Biomarcadores de infeccion por el virus de hepatitis c. MX2008013796A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79552006P 2006-04-26 2006-04-26
PCT/US2007/067421 WO2007127801A2 (en) 2006-04-26 2007-04-25 Hepatitis c virus infection biomarkers

Publications (1)

Publication Number Publication Date
MX2008013796A true MX2008013796A (es) 2009-03-31

Family

ID=38656353

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013796A MX2008013796A (es) 2006-04-26 2007-04-25 Biomarcadores de infeccion por el virus de hepatitis c.

Country Status (13)

Country Link
US (1) US20100028874A1 (enExample)
EP (1) EP2016195A4 (enExample)
JP (1) JP2009535036A (enExample)
KR (1) KR20090023360A (enExample)
CN (1) CN101479389A (enExample)
AU (1) AU2007244824A1 (enExample)
CA (1) CA2650616A1 (enExample)
IL (1) IL194920A0 (enExample)
MX (1) MX2008013796A (enExample)
NO (1) NO20084954L (enExample)
NZ (1) NZ573052A (enExample)
RU (1) RU2008146518A (enExample)
WO (1) WO2007127801A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
JP2009178057A (ja) * 2008-01-29 2009-08-13 Miyazakiken Sangyo Shien Zaidan インターフェロンとリバビリンとの併用治療効果の検出方法および検出キット
KR20110074870A (ko) * 2008-09-24 2011-07-04 버텍스 파마슈티칼스 인코포레이티드 간염을 치료하기 위한 peg-인터페론, 리바비린 및 vx-950을 포함하는 치료 요법
WO2011132086A2 (en) 2010-04-21 2011-10-27 MeMed Diagnostics, Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
CN102178927A (zh) * 2011-03-01 2011-09-14 中国人民解放军军事医学科学院放射与辐射医学研究所 干扰素诱导跨膜蛋白3在制备抗乙型肝炎病毒感染药物中的用途
CN102323426A (zh) * 2011-08-08 2012-01-18 中国人民解放军军事医学科学院放射与辐射医学研究所 用于诊断或筛查丙型肝炎病毒感染的试剂
AU2013217935B2 (en) 2012-02-09 2018-05-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CA2948803A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
RU2730836C2 (ru) 2014-08-14 2020-08-26 Мемед Диагностикс Лтд. Вычислительный анализ биологических данных с применением многообразия и гиперплоскости
CN115054687A (zh) * 2014-08-22 2022-09-16 广州英恩迈生物医药科技有限公司 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
EP3230740B1 (en) 2014-12-11 2025-05-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
WO2017149547A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Analyzing rna for diagnosing infection type
US11274345B2 (en) 2016-06-07 2022-03-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of bacterial and viral infections
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
WO2018011795A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN108379584B (zh) * 2018-04-12 2020-08-11 上海交复生物医药科技有限公司 RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性
CN110448548B (zh) * 2018-05-08 2023-05-05 四川大学华西医院 Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途
KR102289533B1 (ko) * 2019-08-19 2021-08-17 주식회사 테라젠바이오 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램
CN111333710B (zh) * 2020-03-04 2021-12-03 暨南大学 C20orf24蛋白缺失突变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517960A (ja) * 2003-02-18 2006-08-03 ファイザー インコーポレイテッド C型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
US20050282179A1 (en) * 2003-12-05 2005-12-22 Applera Corporation Biomarkers for interferon-alpha response in hepatitis C virus infected patients
US7892735B2 (en) * 2004-12-30 2011-02-22 University Of Louisville Research Foundation, Inc. Genetic markers of schizophrenia spectrum disorders in the sulfotransferase 4a (sult4a) gene

Also Published As

Publication number Publication date
WO2007127801A2 (en) 2007-11-08
KR20090023360A (ko) 2009-03-04
CN101479389A (zh) 2009-07-08
NO20084954L (no) 2009-01-22
AU2007244824A1 (en) 2007-11-08
JP2009535036A (ja) 2009-10-01
EP2016195A4 (en) 2010-03-10
WO2007127801A3 (en) 2008-09-12
IL194920A0 (en) 2009-08-03
NZ573052A (en) 2012-03-30
RU2008146518A (ru) 2010-06-10
EP2016195A2 (en) 2009-01-21
CA2650616A1 (en) 2007-11-08
US20100028874A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
US20100028874A1 (en) Hepatitis c virus infection biomarkers
Ziegler et al. Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19
Donne et al. Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD
Songok et al. Microarray analysis of HIV resistant female sex workers reveal a gene expression signature pattern reminiscent of a lowered immune activation state
Meissner et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
Hoang et al. Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease
He et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race
JP5469744B2 (ja) インターフェロンアルファ応答に関連する遺伝子マーカー
AU2009240021B2 (en) Antiviral therapy
Naggie et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B‐unfavorable genotype patients: Impaired viral kinetics and therapeutic response
Welzel et al. Variants in interferon‐alpha pathway genes and response to pegylated interferon‐Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long‐term treatment against cirrhosis trial
EP2115169B1 (en) Methods for determining drug sensitivity in patients infected with hcv
US10072296B2 (en) Compositions and methods for sjögren's syndrome
EP2191274A1 (en) Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy
CA3180628A1 (en) Treatments for a sub-population of inflammatory bowel disease patients
Schmidt et al. Intravenous immunoglobulins, cyclosporine, and best supportive care in epidermal necrolysis: diverse effects on systemic inflammation
Wang et al. The alarmin IL-33 exacerbates pulmonary inflammation and immune dysfunction in SARS-CoV-2 infection
AU2010325065A1 (en) Markers associated with ribavirin-induced anemia
Goertsches et al. Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks
MacParland et al. Differential expression of interferon alpha inducible genes in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus and healthy donors
Katsounas et al. CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon‐α therapy and toll‐like receptor 3 signalling
HK1130843A (en) Hepatitis c virus infection biomarkers
Ullah et al. Assessment of ubiquitin specific Peptidase-18 gene in peripheral blood of chronic hepatitis C patients treated with direct-acting antiviral drugs
Huang et al. Peripheral blood gene expression profile associated with sustained virologic response after peginterferon plus ribavirin therapy for chronic hepatitis-C genotype 1
Lim et al. The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal